MRK Stock - is Merck's Stock a Good Buy in 2019 - Best Investments Series

TL;DR

Merck is a global healthcare company with four main segments: human health, vaccines, animal health, and alliances. Its largest revenue driver is human health, followed by vaccines.

Transcript

hey YouTube I'm Jimmy in this video I'm gonna walk through my analysis of Merck ticker symbol MRK this is a 19th video in our series where we're analyzing all 30 stocks in the Dow Jones Industrial Average you can see a link to all those other videos in the description below well once we're done with our analysis we're going to take all of that anal... Read More

Key Insights

• 💊 Merck has a diverse portfolio of products, with a focus on prescription medicines, vaccines, and biologic therapies.
• 🧑‍⚕️ The human health segment is the largest revenue driver for Merck.
• 🧑‍⚕️ Vaccines and animal health are also significant contributors to Merck's revenue.
• 🖐️ Collaboration and partnerships play a crucial role in Merck's business, with the alliances segment having potential for significant revenue generation.
• 🪛 Keytruda, a cancer drug, is expected to drive future revenue growth for Merck.
• 🙃 Merck's stock valuation suggests potential upside, making it an appealing investment option.
• 💪 The stability of Merck's business and its defensive nature make it a strong contender for weathering market downturns.

Questions & Answers

Q: What are the main segments of Merck's business?

Merck has four main segments: human health, vaccines, animal health, and alliances. Human health is the largest segment, followed by vaccines, animal health, and alliances.

Q: How does collaboration with other companies contribute to Merck's revenue?

The alliances segment consists of collaborations with other companies. These collaborations can lead to significant revenue generation, as seen in the partnership with a company that created tyrosine kinase inhibitors.

Q: Which segment has been a source of growth for Merck?

The vaccines segment has been a source of growth for Merck. This segment has shown consistent growth in recent years.

Q: What are the key revenue-generating prescription drugs for Merck?

Januvia, a diabetes medicine, is Merck's largest contributor to revenue. Keytruda, a cancer drug, has also shown promising growth and is expected to be a primary driver of revenue in the future.

Summary & Key Takeaways

• Merck is a global healthcare company with a diverse portfolio of prescription medicines, vaccines, biologic therapies, and animal health care products.

• The company has four main segments: human health, vaccines, animal health, and alliances.

• Human health is the largest revenue driver, accounting for about 73% of revenue, followed by vaccines, animal health, and alliances.